Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics (IOVA) pioneers tumor-infiltrating lymphocyte (TIL) therapies for advanced cancers, leading the next generation of personalized immunotherapies. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical milestones, regulatory developments, and strategic initiatives.
Access timely announcements including FDA submissions, clinical trial data publications, manufacturing advancements, and partnership agreements. Our curated collection ensures you stay informed about IOVA developments impacting oncology treatment paradigms and biopharmaceutical innovation.
Key updates cover therapy approvals, research collaborations, financial results, and scientific presentations. All content is verified through primary sources to maintain accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Iovance's latest progress in developing TIL-based therapies for melanoma, cervical cancer, and other solid tumors. Regularly updated to serve as your definitive resource for IOVA-related news analysis.
Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer, announced its participation in several upcoming conferences and events.
Key events include the TD Cowen 5th Annual Oncology Innovation Summit on May 28, 2024, a virtual ASCO Investor/Analyst event on May 31, 2024, the Jefferies Global Healthcare Conference on June 6, 2024, the Goldman Sachs Global Healthcare Conference on June 10, 2024, and the Iovance 2024 Annual Meeting on June 11, 2024.
These events will feature presentations and discussions by senior leadership, with webcasts available at the company's investor relations website.
Iovance Biotherapeutics presented new clinical data for lifileucel combined with pembrolizumab in frontline advanced melanoma at the ASCO 2024 Annual Meeting. The IOV-COM-202 trial showed a 65% objective response rate (ORR) and a 30% complete response rate, with nearly all responses ongoing at a median follow-up of 21.7 months. The results support the ongoing TILVANCE-301 Phase 3 trial. Lifileucel's safety profile as a one-time treatment was favorable compared to continuous regimens. Early interim analysis of ORR could expedite regulatory approval.
On May 16, 2024, Iovance Biotherapeutics announced the approval of inducement stock options for 153,930 shares of its common stock to 30 new non-executive employees. These options were granted under the 2021 Inducement Plan, amended three times since adoption, compliant with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $10.43, the closing price on the grant date, and vests over three years. The plan aims to attract and retain talent in the company's mission to develop innovative cancer therapies.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported strong momentum for Amtagvi™ (Lifileucel) U.S. launch post-FDA approval, with 100+ patients enrolled across 40+ ATCs. Regulatory submissions on track in the EU, UK, and Canada. Lifileucel expansion planned in new markets and indications. Lifileucel in various trials for advanced melanoma, NSCLC, and endometrial cancer. Next-generation TIL pipeline in progress. Manufacturing capacity expansion underway. Financially, revenue was $0.7 million with a net loss of $113.0 million in Q1 2024.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) will release its first quarter 2024 financial results on May 9, 2024. The company specializes in TIL therapies for cancer patients. A conference call and webcast will be held at 4:30 p.m. ET for a corporate update.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) will be presenting at upcoming conferences, showcasing their focus on polyclonal tumor infiltrating lymphocyte therapies for cancer patients.